Loading
A phase 1/2 trial of ivonescimab in pancreatic cancer, run by Shandong Cancer Hospital and Institute, now recruiting.
Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND) is a phase 1/2, interventional study registered as NCT06844422 by Shandong Cancer Hospital and Institute, with a registry enrolment figure of 37 participants, started 2025-02-08 and due to reach its primary completion in 2028-02-18. Interventions recorded: Ivonescimab. Conditions listed: Pancreatic Cancer. Primary outcome: Maximum Tolerated Dose (MTD); Dose-Limiting Toxicity (DLT); Recommended Phase 2 Dose (RP2D). Pancreatic eligibility wording from the registry: "At least one measurable pancreatic cancer lesion, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1". Sites: China. No results are recorded here; the registry entry is the source.
Shares Ivonescimab, SBRT / SABR (stereotactic radiotherapy), Pancreatic cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Ivonescimab, SBRT / SABR (stereotactic radiotherapy), Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares SBRT / SABR (stereotactic radiotherapy), Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Ivonescimab, Pancreatic cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.